Unknown PHASE4 INTERVENTIONAL 1-arm NCT02033018

Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization (AflibxMyopia)

Sponsor: Instituto de Olhos de Goiania

Conditions Choroidal Retinal Neovascularization

Updated 6 times since 2017 Last updated: Jan 9, 2014 Started: Oct 31, 2013 Primary completion: Nov 30, 2014 Completion: Nov 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02033018, this PHASE4 trial focuses on Choroidal Retinal Neovascularization and remains ongoing. Sponsored by Instituto de Olhos de Goiania, it has been updated 6 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE4
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Oct 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Instituto de Olhos de Goiania

Data source: Instituto de Olhos de Goiania

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Goiânia, Brazil